Junjiang Wang

Dr. Junjiang Wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in Advanced Science
Verified
Journal Article
Open access
ZPZihao Pan
Zihao Pan
JZJun Zheng
Jun Zheng
JZJiebin Zhang
Jiebin Zhang
JLJiatong Lin
Jiatong Lin
JLJianguo Lai
Jianguo Lai
YLYong Li
Yong Li
Oxaliplatin is commonly used in chemotherapeutic regimens for colorectal cancer (CRC) after surgical resection. However, acquired chemoresistance seriously affects the curative effect in CRC patients, and the mechanism is still unclear. Here, a circular RNA, circATG4B is identified, which plays an important role in oxaliplatin resistance in CRC. circATG4B expression is found to be increased in exosomes secreted by oxaliplatin‐resistant CRC cells. In addition, the results suggest that circATG4B induces oxaliplatin resistance by promoting autophagy. Further in vivo and in vitro studies indicate that the effect of circATG4B is attributed to its potential to encode a novel protein, circATG4B‐222aa. Next, circATG4B‐222aa is found to function as a decoy to competitively interact with TMED10 and prevent TMED10 from binding to ATG4B, which leads to increased autophagy followed by induction of chemoresistance. Therefore, this study reveals that exosomal circATG4B participates in the decreased chemosensitivity of CRC cells, providing a new rationale for a potential therapeutic target for oxaliplatin resistance in CRC.

1 April 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
CHChengzhi Huang
Chengzhi Huang
JLJianhua Liu
Jianhua Liu
LXLishu Xu
Lishu Xu
WHWeixian Hu
Weixian Hu
JWJunjiang Wang
Junjiang Wang
XYXueqing Yao
Xueqing Yao
Purpose: There is mounting evidence to indicate that microRNA-17 (miR-17) is expressed and functionally involved in human cancers. However, the molecular mechanism underlying the role of miR-17 in colorectal cancer (CRC) remains largely unclear. This study aims to reveal the biological function of miR-17 in colorectal cancer. Materials and methods: The expression of miR-17 in CRC cells and tissues was examined using qRT-PCR. Cell proliferation and migration assays were performed after transfection with an miR-17 mimic and inhibitors. The potential gene targets of miR-17 were predicted by bioinformatics analysis and further validated by PCR, Western blot and dual luciferase reporter assays. Results: The expression of miR-17 was significantly upregulated in CRC cell lines and tissues and may imply poor prognosis. miR-17 upregulation promoted cell invasion and migration in CRC cell lines in vitro, while downregulation of miR-17 inhibited tumor progression. SIK1 was identified as a potential direct target of miR-17 by dual luciferase reporter assay, and its downregulation in CRC may suggest poor prognosis. Conclusions: Our study indicated that upregulated miR-17 may promote the progression of CRC and may exert its function as a tumor suppressor miRNA by targeting SIK1.

7 July 2022 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
WDWenfei Diao
Wenfei Diao
JZJiabin Zheng
Jiabin Zheng
YLYong Li
Yong Li
JWJunjiang Wang
Junjiang Wang
SXSonghui Xu
Songhui Xu
Post‑translational modifications of histones by histone demethylases have an important role in the regulation of gene transcription and are implicated in cancers. Recently, the family of lysine (K)‑specific demethylase (KDM) proteins, referring to histone demethylases that dynamically regulate histone methylation, were indicated to be involved in various pathways related to cancer development. To date, numerous studies have been conducted to explore the effects of KDMs on cancer growth, metastasis and drug resistance, and a majority of KDMs have been indicated to be oncogenes in both leukemia and solid tumors. In addition, certain KDM inhibitors have been developed and have become the subject of clinical trials to explore their safety and efficacy in cancer therapy. However, most of them focus on hematopoietic malignancy. This review summarizes the effects of KDMs on tumor growth, drug resistance and the current status of KDM inhibitors in clinical trials.

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
HFHuolun Feng
Huolun Feng
JZJiabin Zheng
Jiabin Zheng
CZChengbin Zheng
Chengbin Zheng
ZDZhenru Deng
Zhenru Deng
QLQianchao Liao
Qianchao Liao
YLYong Li
Yong Li
Background: In adenocarcinoma of esophagogastric junction (AEG), the relationship between tumor size (TS) and lymph node metastasis (LNM) is unclear. This study aimed to explore the relationship between TS and LNM, and to construct a prediction model for LNM.

9 January 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
JLJinghui Li
Jinghui Li
YMYongli Ma
Yongli Ma
LWLiang Wen
Liang Wen
GZGuosheng Zhang
Guosheng Zhang
CHChengzhi Huang
Chengzhi Huang
XYXueqing Yao
Xueqing Yao
Background: Tumor budding (TB) is a negative prognostic factor in colorectal cancer; however, its prognostic impact following neoadjuvant therapy for patients with rectal cancer remains unclear. This study aims to assess the prognostic impact of TB and the correlation between TB and other pathological features in patients with rectal cancer after neoadjuvant therapy. Methods: A comprehensive search of PubMed, Embase, Cochrane, Scopus, CNKI, Wanfang, and ClinicalKey databases was conducted for studies on the prognosis of TB in rectal cancer after neoadjuvant therapy from the inception of the databases to January 2023, and the final literature included was determined using predefined criteria. Quality assessment of the studies included, extraction of general and prognostic information from them, and meta-analyses were carried out progressively. Results: A total of 11 studies were included, and the results of the meta-analysis showed that high-grade tumor budding (TB-1) increased the risk of poor 5-year disease-free survival (HR = 1.75, 95% CI 1.38–2.22, P < 0.00001), 5-year overall survival (HR = 1.77, 95% CI 1.21–2.59, P = 0.003), local recurrence (OR = 4.15, 95% CI 1.47–11.75, P = 0.007), and distant metastasis (OR = 5.36, 95% CI 2.51–11.44, P < 0.0001) in patients with rectal cancer after neoadjuvant therapy. TB-1 was significantly associated with poor differentiation and lymphatic, perineural, and venous invasion. Conclusion: Tumor budding is significantly correlated with unfavorable prognosis and poor pathological characteristics following neoadjuvant therapy for rectal cancer. We anticipate more high-quality, prospective studies in the future to confirm our findings. Systematic review registration: PROSPERO CRD42022377564.

5 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JCJierong Chen
Jierong Chen
QHQunsheng Huang
Qunsheng Huang
YLYi-Qi Li
Yi-Qi Li
ZLZhi Li
Zhi Li
JZJiabin Zheng
Jiabin Zheng
YLYong Li
Yong Li
Adenocarcinoma of the esophagogastric junction (AEG) is a type of tumor that arises at the anatomical junction of the esophagus and stomach. Although AEG is commonly classified as a subtype of gastric adenocarcinoma (GAC), the tumor microenvironment (TME) of AEG remains poorly understood. To address this issue, we conducted single-cell RNA sequencing (scRNA-seq) on tumor and adjacent normal tissues from four AEG patients and performed integrated analysis with publicly available GAC single-cell datasets. Our study for the first time comprehensively deciphered the TME landscape of AEG, where heterogeneous AEG malignant cells were identified with diverse biological functions and intrinsic malignant nature. We also depicted transcriptional signatures and T cell receptor (TCR) repertoires for T cell subclusters, revealing enhanced exhaustion and reduced clone expansion along the developmental trajectory of tumor-infiltrating T cells within AEG. Notably, we observed prominent enrichment of tumorigenic cancer-associated fibroblasts (CAFs) in the AEG TME compared to GAC. These CAFs played a critical regulatory role in the intercellular communication network with other cell types in the AEG TME. Furthermore, we identified that the accumulation of CAFs in AEG might be induced by malignant cells through FGF-FGFR axes. Our findings provide a comprehensive depiction of the AEG TME, which underlies potential therapeutic targets for AEG patient treatment.